back to US directory
us clinical guidance

Urticaria and angioedema outside anaphylaxis

Acute urticaria phenotype, important mimics and emergency safety boundaries, with chronic drug sequencing kept outside scope.

JurisdictionUnited States
Source check2026-08-20
Clinical reviewiatroX editorial team · Clinical editorial review · reviewed 2026-08-20 · due 2027-08-20
AudienceUnited States healthcare professionals
This is an iatroX educational summary of named United States sources, not an official guideline. It does not replace the complete source documents, local policy, specialist advice or clinical judgement. Use the named authority, current FDA labeling, applicable state law, payer rules and local protocol where relevant.

Scope of this summary

Children and adults with wheals, angioedema, or both after anaphylaxis has been excluded. The 2014 US parameter is used for classification and acute-urticaria assessment boundaries. Chronic drug sequencing, hereditary or acquired bradykinin-mediated angioedema, vasculitis and medication-specific emergencies require separate current pathways.
sources for this section:JTFPP urticaria 2014

The Bottom Line

  • Confirm the phenotype: typical urticarial wheals are itchy, evanescent and usually resolve from one site within 24 hours without bruising; fixed, painful, purpuric or scarring lesions suggest another diagnosis.
  • Classify symptoms lasting six weeks or less as acute and longer disease as chronic, then distinguish spontaneous from reproducible inducible triggers rather than ordering indiscriminate allergy panels.
  • This page does not provide antihistamine up-dosing or a chronic drug sequence; use a finalized current authority and current FDA labeling for those treatment decisions.
  • Do not extrapolate the 2014 acute-assessment material into a current omalizumab, dupilumab, remibrutinib, corticosteroid or other advanced-treatment sequence.
sources for this section:JTFPP urticaria 2014

Practical clinical workflow

1
First check for hypotension, respiratory compromise, rapidly progressing tongue or laryngeal swelling and multisystem anaphylaxis; move immediately to the anaphylaxis pathway when present.
2
Record lesion duration at one site, itch versus pain, residual bruising, isolated swelling, fever, joint or systemic symptoms, new medicines, infection, foods, stings and physical triggers and review photographs when the eruption has cleared.
3
Use the 2014 source only within its classification and acute-disease assessment role. Chronic-drug selection, dose escalation and advanced therapy are outside this summary.
4
Isolated recurrent angioedema requires its own exact cause-specific authority rather than extrapolation from an urticaria pathway.
sources for this section:JTFPP urticaria 2014JTFPP anaphylaxis 2023

Safety boundaries and escalation

  • Tongue or throat swelling, voice change, stridor, respiratory distress, syncope or shock needs emergency airway and anaphylaxis assessment; an oral antihistamine is not adequate rescue treatment.
  • Angioedema without wheals after an ACE inhibitor or with abdominal attacks, family history or poor response to epinephrine and antihistamines can be bradykinin mediated and needs urgent cause-specific evaluation.
  • Lesions lasting longer than 24 hours in one location, pain, purpura, fever, arthralgia or systemic illness should prompt evaluation for urticarial vasculitis, infection, autoinflammatory disease or another mimic.
  • Chronic corticosteroid use, antihistamine dose escalation and advanced-treatment selection are outside this page and require current treatment guidance, FDA labeling and patient-specific review.
sources for this section:JTFPP urticaria 2014WAO/EAACI HAE 2021JTFPP anaphylaxis 2023

Localization

The 2014 US parameter is used only for classification and acute-disease boundaries, the WAO/EAACI source only for hereditary-angioedema separation and the 2023 JTFPP source for anaphylaxis separation. No advanced or European chronic-treatment sequence is presented as domestic policy.
sources for this section:JTFPP urticaria 2014WAO/EAACI HAE 2021JTFPP anaphylaxis 2023

Source documents

Use the linked source documents for complete recommendations, evidence grading, exclusions and implementation detail.

  1. AAAAI/ACAAI Joint Task Force on Practice ParametersThe Diagnosis and Management of Acute and Chronic Urticaria: 2014 Updatepublished 2014-05-01 · accessed 2026-08-20
    view source
  2. World Allergy Organization and European Academy of Allergy and Clinical ImmunologyThe International WAO/EAACI Guideline for the Management of Hereditary Angioedema — 2021 Revision and UpdateDOI 10.1111/all.15214 · 2021 revision; published online 2022-02-03; print issue July 2022 · published 2022-02-03 · accessed 2026-08-20
    view source
  3. AAAAI/ACAAI Joint Task Force on Practice ParametersAnaphylaxis: A 2023 Practice Parameter UpdateDOI 10.1016/j.anai.2023.09.015 · published online 2023-12-18; print issue February 2024 · published 2023-12-18 · accessed 2026-08-20
    view source
continue the learning

From guidance to deliberate practice and evidence

Choose what happens next. iatroX can carry this page's jurisdiction, source-check date and released version into an editable learning record, support your reflection, or let you browse the regional question bank while keeping this topic visible. No action records completion, starts a session or awards CPD/CME credit automatically.

Add this guidance review to CPD/CMEOpen an editable learning-log record with this page’s provenance attached. You confirm the activity, time, reflection and mappings.Reflect on this with TutorUse optional prompts to consider what you learned and what—if anything—you may change. Suggestions are never inserted automatically.Browse the US question bankKeep this guidance topic in view, then choose your exam and filters. No session starts automatically.
Found a source update or regional discrepancy? Tell the iatroX editorial team.